Disposition of Caspofungin: Role of Distribution in Determining Pharmacokinetics in Plasma

Antimicrobial Agents and Chemotherapy

Volumn 48, Issue 3, 2004, Pages 815-823

  Stone, Julie A ^a   Xu, Xin ^a   Winchell, Gregory A ^a   Deutsch, Paul J ^a   Pearson, Paul G ^a   Migoya, Elizabeth M ^a   Mistry, Goutam C ^a   Xi, Liwen ^a   Miller, Alisha ^a   Sandhu, Punam ^a   Singh, Romi ^a   DeLuna, Florencia ^a   Dilzer, Stacy C ^b   Lasseter, Kenneth C ^b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Clinical Pharmacology Associates Miami   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; CASPOFUNGIN;

ADULT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BIOTRANSFORMATION; CLINICAL TRIAL; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG UPTAKE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; MALE; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; RADIOACTIVITY; RAT; TISSUE DISTRIBUTION;

ADULT; ALGORITHMS; ANIMALS; ANTIFUNGAL AGENTS; AREA UNDER CURVE; BIOTRANSFORMATION; BLOOD PROTEINS; ERYTHROCYTES; FECES; HALF-LIFE; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PEPTIDES; PEPTIDES, CYCLIC; PROTEIN BINDING; RATS;

EID: 10744227193     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.48.3.815-823.2004     Document Type: Article

References (16)

1. Arathoon, E. G., E. Gotuzzo, L. M. Noriega, R. S. Berman, M. J. DiNubile, and C. A. Sable. 2002. A randomized, double-blind, multicenter study of caspofungin versus amphotericin in the treatment of oropharyngeal and esophageal candidiasis. Antimicrob. Agents Chemother. 46:451-457.
2. Balani, S. K., X. Xu, B. H. Arison, M. V. Silva, A. Gries, F. A. DeLuna, D. Cui, P. H. Kari, T. Ly, C. E. C. A. Hop, R. Singh, M. A. Wallace, D. C. Dean, J. H. Lin, P. G. Pearson, and T. A. Baillie. 2000. Metabolites of caspofungin acetate, a potent antifungal agent, in human plasma and urine. Drug Metab. Dispos. 28:1274-1278.
3. Bartizal, K., C. J. Gill, G. K. Abruzzo, A. M. Flattery, L. Kong, P. M. Scott, J. G. Smith, C. E. Leighton, A. Bouffard, J. F. Dropinski, and J. Balkovec. 1997. In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872). Antimicrob. Agents Chemother. 41:2326-2332.
4. o derivatives. J. Med. Chem. 37:222-225.
5. Bowman, J. C., P. Scott Hicks, M. B. Kurtz, H. Rosen, D. M. Schmatz, P. A. Liberator, and C. M. Douglas. 2002. The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro. Antimicrob. Agents Chemother. 46:3001-3012.
6. Gibaldi, M., and D. Perrier. 1982. Pharmacokinetics, 2nd ed., p. 211-219. Marcel Dekker, Inc., New York, N.Y.
7. Krishnarao, T. V., and J. N. Galgiani. 1997. Comparison of the in vitro activities of the echinocandin LY303366, the pneumocandin MK-0991, and fluconazole against Candida species and Crypotococcus neoformans. Antimicrob. Agents Chemother. 41:1957-1960.
8. Lowry, O. H., N. J. Rosebrough, A. L. Farr, and R. J. Randall. 1951. Protein measurement with the folin phenol reagent. J. Biol. Chem. 193:265-275.
9. Mora-Duarte, J., R. Betts, C. Rotstein, A. L. Colombo, L. Thompson-Moya, J. Smietana, R. Lupinacci, C. Sable, N. Kartsonis, J. Perfect, et al. 2002. Comparison of caspofungin and amphotericin B for invasive candidiasis, N. Engl. J. Med. 347:2020-2029.
10. Rowland, M., and T. Tozer. 1989. Clinical pharmacokinetics concepts and applications, 2nd ed., p. 438-450, Lea and Febiger, Philadelphia, Pa.
11. Sandhu, P., X. Xu, P. J. Bondiskey, S. K. Balani, M. L. Morris, Y. S. Tang, A. R. Miller, and P. G. Pearson. Disposition of caspofungin, a novel antifungal agent, in mice, rats, rabbits, and monkeys. Antimicrob. Agents Chemother., in press.
12. Schwartz, M., W. Kline, and B. Matuszewski. 1997. Determination of a cyclic hexapeptide (L-743,872), a novel pneumocandin antifungal agent in human plasma and urine by high-performance liquid chromatography with fluorescence detection. Anal. Chem. Acta 352:299-307.
13. Stone, J. A., S. D. Holland, P. J. Wickersham, A. Sterrett, M. Schwartz, C. Bonfiglio, M. Hesney, G. A. Winchell, P. J. Deutsch, H. Greenberg, T. L. Hunt, and S. A. Waldman. 2002. Single- and multiple-dose pharmacokinetics of caspofungin in healthy men. Antimicrob. Agents Chemother. 46:739-745.
14. Vazquez, J. A., M. Lynch, D. Boikov, and J. D. Sobel. 1997. In vitro activity of a new pneumocandin antifungal, L-743,872, against azole-susceptible and -resistant Candida species. Antimicrob. Agents Chemother. 41:1612-1614.
15. Villanueva, A., E. G. Arathoon, E. Gotuzzo, R. S. Berman, M. J. DiNubile, and C. A. Sable. 2001. A randomized double-blind study of caspofungin versus amphotericin for the treatment of Candida esophagitis. Clin. Infect. Dis. 33:1529-1535.
16. Villanueva, A., E. Gotuzzo, E. Arathoon, L. M. Noriega, N. Kartsonis, R. Lupinacci, J. Smietana, R. S. Berman, M. J. DiNubile, and C. A. Sable. 2002. A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. Am. J. Med. 113:294-299.